Verve 102: Can One Gene-Editing Treatment Lower Bad Cholesterol?

For people with very high LDL cholesterol, treatment often involves taking medicines regularly over long periods. Researchers are now studying whether gene editing could offer a different approach through a single treatment.

Verve 102 is an experimental gene-editing treatment being developed to lower LDL cholesterol by targeting the PCSK9 gene in liver cells. It is designed to be given as a one-time intravenous infusion and uses a technology known as in vivo base editing, which allows a targeted change to DNA inside the body.

The treatment is being investigated for people with conditions such as heterozygous familial hypercholesterolaemia and premature coronary artery disease, where additional LDL cholesterol reduction may be needed.

Advertisement

Verve 102 remains an investigational treatment. It has not been approved for routine use and should not currently be considered a replacement for statins or other established cholesterol-lowering medicines.

PCSK9 plays an important role in how the body regulates LDL cholesterol. The liver contains LDL receptors that help remove LDL, commonly known as bad cholesterol, from the bloodstream. PCSK9 promotes the breakdown of some of these receptors.

When PCSK9 activity is reduced, more LDL receptors remain available on liver cells. This allows the liver to remove more LDL cholesterol from the bloodstream.

Verve 102 is designed to make a specific change to the PCSK9 gene, reducing the production of functional PCSK9 protein. Unlike medicines that temporarily block a protein, gene editing is intended to create a genetic change that could potentially produce a longer-lasting effect.

Early findings from the Phase 1b Heart 2 trial have attracted attention after researchers observed reductions in both PCSK9 and LDL cholesterol following a single infusion.

Across the doses studied, PCSK9 levels decreased by approximately 51% to 88%, while LDL cholesterol levels fell by approximately 9% to 62%. At the highest tested dose of 1 mg per kg, LDL cholesterol dropped by about 62%, corresponding to an average reduction of around 78 mg per dL.

The reduction was reported during up to 18 months of follow-up, indicating that the treatment's effects can persist well beyond the initial infusion.

However, the findings are still considered early clinical evidence. The Phase 1b study was primarily designed to evaluate safety, tolerability and biological effects. Its size and design were not sufficient to determine whether Verve 102 can prevent major cardiovascular events such as heart attacks or strokes.

Verve 102 is designed to make a durable genetic change, which is why researchers are investigating whether a single treatment could produce long-lasting LDL cholesterol reduction.

However, there is not yet enough evidence to say that the treatment permanently lowers cholesterol for a person's lifetime. Human data currently extend to up to 18 months of follow-up, which is encouraging but cannot establish what the effects or risks might be over several decades.

For this reason, Verve 102 is more accurately described as a potentially durable, one-time gene-editing treatment rather than a treatment proven to permanently lower cholesterol.

Verve 102 is also not currently a replacement for statins. Statins remain established medicines for lowering LDL cholesterol and reducing cardiovascular risk. Other options, including ezetimibe and PCSK9 inhibitors, are also available for people who require additional LDL reduction.

Before Verve 102 could become part of routine cholesterol treatment, researchers would need to establish its long-term safety, durability and effectiveness in reducing cardiovascular events.

The treatment is significant because it aims to target a genetic pathway involved in cholesterol regulation through a single intervention. If future studies demonstrate that the approach is safe and its effects remain durable, it could potentially change how some people with inherited or difficult-to-treat high cholesterol are managed.

For now, Verve 102 remains experimental. Early results suggest that a single gene-editing infusion can substantially reduce PCSK9 and LDL cholesterol levels, but considerably more research is needed before the treatment can be considered an approved option for routine cholesterol care.